Hematologic complications in patients exposed to poly-ADP ribose polymerase inhibitors.
Hematologic complications in patients exposed to poly-ADP ribose polymerase inhibitors. Haematologica. 2026 Jan 29.
PMID: 41609051
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies.
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies. Br J Haematol. 2026 Jan; 208(1):343-347.
PMID: 41139955
Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination.
Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination. J Natl Cancer Inst. 2025 Sep 01; 117(9):1764-1773.
PMID: 40163691
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults.
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025 Aug 14; 15(1):138.
PMID: 40813576
The Current State of Palliative Care Research for Adolescents and Young Adults With Cancer: A Systematic Review and Meta-Thematic Analysis of Empirical Literature.
The Current State of Palliative Care Research for Adolescents and Young Adults With Cancer: A Systematic Review and Meta-Thematic Analysis of Empirical Literature. Psychooncology. 2025 Jul; 34(7):e70228.
PMID: 40660632
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy.
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy. EJHaem. 2025 Jun; 6(3):e70078.
PMID: 40521395
Targeting the CD74 signaling axis suppresses inflammation and rescues defective hematopoiesis in RUNX1-familial platelet disorder.
Targeting the CD74 signaling axis suppresses inflammation and rescues defective hematopoiesis in RUNX1-familial platelet disorder. Sci Transl Med. 2025 Jan 08; 17(780):eadn9832.
PMID: 39772771
CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia.
CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia. EJHaem. 2025 Feb; 6(1):e1076.
PMID: 39866945
Prognostic impact of 'multi-hit' <i>versus</i> 'single-hit' <i>TP53</i> alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases.
Prognostic impact of 'multi-hit' <i>versus</i> 'single-hit' <i>TP53</i> alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases. Haematologica. 2024 11 01; 109(11):3533-3542.
PMID: 38813716
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica. 2024 Nov 01; 109(11):3739-3744.
PMID: 38618681